Institutionalizing M&A Excellence In Health Care
M&A deals, particularly smaller ones, are the lifeblood of the health care industry. Despite evident success in dealmaking, McKinsey says that pharma and medtech firms can benefit by bringing better consistency, transparency and accountability to their M&A programs.
You may also be interested in...
Medtech M&A activity has been on the rise for several years along with a surge in the number of higher-valued mega-deals, those worth at least $1 billion. Yet a survey of all deals with known values indicates that median deal value has actually declined.